entacapone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
catechol-O-methyltransferase (COMT) inhibitors 1018 130929-57-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • entacapone
  • entacom
  • comtess
Entacapone is a selective and reversible inhibitor of COMT. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease.
  • Molecular weight: 305.29
  • Formula: C14H15N3O5
  • CLOGP: 2.66
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 130.38
  • ALOGS: -3.58
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 87.35 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 42 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.27 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.274 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 22.803 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 17.022 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 8.974 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 6.240 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 3.720 % High 1
herg hERG pIC50 4.773 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 14.928 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 14.962 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 1.910 % High 1
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK16,CDK19,CDK2,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FGFR1,FLT3,FLT4,GRK2,GRK3,GSK3A,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K1,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM1,PIM2,PIM3,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,PTK2,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 96
kinase-selectivity-class AXL,BRAF,CDK4,CDK9,DDR1,DYRK1B,EPHB4,GRK2,MAP2K6,MAPK7,PRKDC,STK33,SYK,TEK,TTK 15
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 9.183 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 10.046 High 1
mh-clint Mouse hepatocyte intrinsic clearance 25.410 High 1
mppb Mouse plasma protein binding (% unbound) 4.390 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.350 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 1.850 % High 1
rat-kpuu-brain Rat brain Kpuu 0.083 % High 1
rh-clint Rat hepatocyte intrinsic clearance 45.920 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 79.590 % High 1
rppb Rat plasma protein binding (% unbound) 0.990 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 918.333 uM High 1

Approvals:

DateAgencyCompanyOrphan
Oct. 19, 1999 FDA ORION PHARMA
Feb. 18, 2011 EMA Teva Pharma B.V.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 509.71 30.06 144 3783 36390 90588130
On and off phenomenon 225.92 30.06 45 3882 2498 90622022
Hallucination 224.30 30.06 90 3837 65869 90558651
Dystonia 154.02 30.06 48 3879 16771 90607749
Hallucination, visual 131.35 30.06 46 3881 23046 90601474
Psychotic disorder 117.81 30.06 46 3881 31184 90593336
Therapeutic response shortened 109.09 30.06 40 3887 22839 90601681
Freezing phenomenon 96.50 30.06 21 3906 1791 90622729
Muscle rigidity 94.95 30.06 32 3895 14277 90610243
Mutism 91.41 30.06 20 3907 1749 90622771
Delusion 88.09 30.06 30 3897 13810 90610710
Acute psychosis 85.43 30.06 21 3906 3057 90621463
Stoma site discharge 78.28 30.06 18 3909 1971 90622549
Impulse-control disorder 73.05 30.06 15 3912 967 90623553
Compulsive shopping 70.63 30.06 14 3913 755 90623765
Dopamine dysregulation syndrome 68.43 30.06 11 3916 175 90624345
Aggression 65.71 30.06 29 3898 26639 90597881
Camptocormia 63.44 30.06 11 3916 282 90624238
Orthostatic hypotension 61.80 30.06 32 3895 41795 90582725
Gait disturbance 58.70 30.06 64 3863 260432 90364088
Parkinsonism hyperpyrexia syndrome 58.63 30.06 10 3917 232 90624288
Stereotypy 58.58 30.06 11 3916 445 90624075
Fall 55.75 30.06 85 3842 481725 90142795
Tremor 53.83 30.06 48 3879 153125 90471395
Neuroleptic malignant syndrome 52.56 30.06 21 3906 15075 90609445
Bradykinesia 52.30 30.06 17 3910 6771 90617749
Sudden onset of sleep 49.81 30.06 10 3917 575 90623945
Parkinsonian gait 49.70 30.06 10 3917 582 90623938
Dysphagia 47.19 30.06 39 3888 112239 90512281
Gambling 44.36 30.06 8 3919 258 90624262
Wrong technique in product usage process 43.57 30.06 31 3896 71540 90552980
Pleurothotonus 41.60 30.06 10 3917 1325 90623195
Balance disorder 41.37 30.06 34 3893 97046 90527474
Stoma site pain 41.00 30.06 10 3917 1407 90623113
Stoma site erythema 40.46 30.06 10 3917 1486 90623034
Therapeutic product effect variable 40.18 30.06 10 3917 1529 90622991
Device issue 39.08 30.06 21 3906 29516 90595004
Impulsive behaviour 39.02 30.06 10 3917 1720 90622800
Logorrhoea 39.00 30.06 11 3916 2716 90621804
Hyperkinesia 37.99 30.06 10 3917 1909 90622611
Speech disorder 37.97 30.06 24 3903 45561 90578959

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 343.29 28.57 132 6155 25258 42589790
On and off phenomenon 315.12 28.57 78 6209 3389 42611659
Hallucination 256.74 28.57 138 6149 57369 42557679
Freezing phenomenon 204.78 28.57 49 6238 1840 42613208
Hallucination, visual 190.16 28.57 82 6205 20938 42594110
Muscle rigidity 181.89 28.57 68 6219 11991 42603057
Gambling disorder 171.64 28.57 42 6245 1734 42613314
Hypersexuality 168.31 28.57 41 6246 1661 42613387
Delusion 99.81 28.57 47 6240 14687 42600361
Fall 92.62 28.57 141 6146 234379 42380669
Cognitive disorder 81.68 28.57 55 6232 34117 42580931
Tremor 81.21 28.57 85 6202 96844 42518204
Bradykinesia 79.53 28.57 30 6257 5406 42609642
Dopamine dysregulation syndrome 73.28 28.57 17 6270 556 42614492
Akinesia 68.60 28.57 22 6265 2450 42612598
Hyperkinesia 67.91 28.57 21 6266 2077 42612971
Gait disturbance 61.58 28.57 74 6213 97926 42517122
Dysphagia 61.27 28.57 64 6223 72655 42542393
Stoma site discharge 57.32 28.57 17 6270 1459 42613589
Confusional state 55.31 28.57 93 6194 167504 42447544
Parkinson's disease 54.73 28.57 16 6271 1306 42613742
Mobility decreased 53.10 28.57 43 6244 35263 42579785
Dementia 52.98 28.57 32 6255 16448 42598600
Reduced facial expression 52.39 28.57 16 6271 1517 42613531
Therapeutic product effect variable 52.24 28.57 19 6268 3090 42611958
Device dislocation 50.01 28.57 24 6263 7807 42607241
Agitation 49.56 28.57 54 6233 64260 42550788
Neuroleptic malignant syndrome 45.25 28.57 32 6255 21440 42593608
Stoma site pain 43.55 28.57 12 6275 791 42614257
Persecutory delusion 42.64 28.57 17 6270 3547 42611501
Jealous delusion 41.08 28.57 10 6277 403 42614645
Aggression 41.03 28.57 41 6246 44122 42570926
Abnormal dreams 40.01 28.57 21 6266 8250 42606798
Irritability 39.65 28.57 33 6254 28095 42586953
Impulse-control disorder 39.57 28.57 13 6274 1562 42613486
Psychotic disorder 38.56 28.57 33 6254 29175 42585873
Stereotypy 38.46 28.57 11 6276 831 42614217
Colitis microscopic 37.68 28.57 15 6272 3118 42611930
Posture abnormal 37.18 28.57 14 6273 2507 42612541
Stoma site erythema 36.48 28.57 11 6276 999 42614049
Dystonia 36.44 28.57 23 6264 12767 42602281
Device issue 35.29 28.57 23 6264 13486 42601562
Therapeutic response shortened 35.22 28.57 23 6264 13531 42601517
Compulsive shopping 35.04 28.57 9 6278 452 42614596
Restlessness 34.50 28.57 31 6256 29218 42585830
Memory impairment 33.27 28.57 39 6248 50183 42564865
Mania 32.66 28.57 20 6267 10527 42604521
Parkinsonism hyperpyrexia syndrome 32.20 28.57 8 6279 351 42614697
Paranoia 32.11 28.57 22 6265 14004 42601044
Illusion 32.04 28.57 10 6277 1019 42614029
Delirium 30.25 28.57 38 6249 52481 42562567
Somatic delusion 30.19 28.57 6 6281 92 42614956
Tricuspid valve sclerosis 29.39 28.57 5 6282 30 42615018
Stoma site inflammation 29.05 28.57 8 6279 526 42614522

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 673.70 27.93 220 8171 51226 110529682
On and off phenomenon 402.86 27.93 88 8303 4336 110576572
Hallucination 384.24 27.93 176 8215 101256 110479652
Hallucination, visual 307.89 27.93 115 8276 39490 110541418
Freezing phenomenon 215.90 27.93 48 8343 2561 110578347
Gambling disorder 196.16 27.93 43 8348 2148 110578760
Muscle rigidity 194.79 27.93 72 8319 23959 110556949
Hypersexuality 178.84 27.93 39 8352 1901 110579007
Dystonia 161.36 27.93 64 8327 25741 110555167
Delusion 141.86 27.93 57 8334 23698 110557210
Psychotic disorder 136.89 27.93 70 8321 50867 110530041
Therapeutic response shortened 133.04 27.93 58 8333 29525 110551383
Dopamine dysregulation syndrome 131.69 27.93 25 8366 602 110580306
Impulse-control disorder 115.72 27.93 28 8363 2166 110578742
Bradykinesia 112.59 27.93 39 8352 10749 110570159
Tremor 107.01 27.93 102 8289 202130 110378778
Fall 106.42 27.93 175 8216 603307 109977601
Akinesia 101.45 27.93 28 8363 3639 110577269
Neuroleptic malignant syndrome 97.89 27.93 49 8342 34010 110546898
Aggression 97.60 27.93 59 8332 59151 110521757
Stereotypy 96.84 27.93 21 8370 996 110579912
Gait disturbance 91.51 27.93 109 8282 278099 110302809
Parkinsonism hyperpyrexia syndrome 89.17 27.93 18 8373 600 110580308
Compulsive shopping 88.72 27.93 19 8372 849 110580059
Hyperkinesia 86.64 27.93 24 8367 3160 110577748
Dysphagia 86.04 27.93 80 8311 153520 110427388
Therapeutic product effect variable 85.67 27.93 23 8368 2695 110578213
Stoma site discharge 85.03 27.93 23 8368 2772 110578136
Acute psychosis 80.18 27.93 25 8366 4962 110575946
Irritability 77.14 27.93 47 8344 47762 110533146
Mutism 73.50 27.93 21 8370 3092 110577816
Agitation 73.38 27.93 64 8327 112987 110467921
Cognitive disorder 68.06 27.93 55 8336 87456 110493452
Device issue 63.65 27.93 37 8354 34498 110546410
Orthostatic hypotension 63.20 27.93 47 8344 66202 110514706
Parkinson's disease 62.85 27.93 16 8375 1523 110579385
Confusional state 60.72 27.93 119 8272 468561 110112347
Stoma site pain 58.99 27.93 16 8375 1947 110578961
Reduced facial expression 57.43 27.93 18 8373 3633 110577275
Logorrhoea 55.92 27.93 19 8372 4938 110575970
Dementia 55.91 27.93 33 8358 31640 110549268
Parkinsonian gait 53.05 27.93 13 8378 1059 110579849
Sudden onset of sleep 52.97 27.93 12 8379 696 110580212
Camptocormia 51.68 27.93 11 8380 477 110580431
Mania 51.29 27.93 27 8364 20769 110560139
Energy increased 49.09 27.93 16 8375 3658 110577250
Jealous delusion 46.34 27.93 10 8381 463 110580445
Illusion 44.97 27.93 13 8378 1994 110578914
Persecutory delusion 44.23 27.93 17 8374 6274 110574634
Behaviour disorder 43.63 27.93 19 8372 9628 110571280
Psychomotor hyperactivity 43.50 27.93 24 8367 20253 110560655
Gambling 42.92 27.93 9 8382 363 110580545
Posture abnormal 42.30 27.93 15 8376 4423 110576485
Progressive supranuclear palsy 41.26 27.93 8 8383 216 110580692
Device dislocation 38.33 27.93 26 8365 31678 110549230
Delirium 38.02 27.93 49 8342 134976 110445932
Resting tremor 37.90 27.93 11 8380 1712 110579196
Somnolence 37.80 27.93 75 8316 297374 110283534
Stoma site infection 37.45 27.93 11 8380 1784 110579124
Arthralgia 37.38 27.93 7 8384 779625 109801283
Balance disorder 37.13 27.93 45 8346 116515 110464393
Death 36.40 27.93 126 8265 698743 109882165
Paranoia 36.08 27.93 22 8369 22352 110558556
Abnormal behaviour 35.67 27.93 27 8364 39012 110541896
Stoma site erythema 35.66 27.93 11 8380 2106 110578802
Abnormal dreams 35.57 27.93 18 8373 12762 110568146
Blood creatine phosphokinase increased 35.08 27.93 35 8356 73042 110507866
Impulsive behaviour 34.64 27.93 12 8379 3303 110577605
Nocturia 33.43 27.93 19 8372 16971 110563937
Wrong technique in product usage process 33.31 27.93 37 8354 87311 110493597
Hypomania 33.24 27.93 16 8375 10194 110570714
Restlessness 32.81 27.93 30 8361 56229 110524679
Tricuspid valve sclerosis 32.71 27.93 5 8386 30 110580878
Torticollis 31.13 27.93 11 8380 3210 110577698
Speech disorder 30.50 27.93 30 8361 61539 110519369
Pleurothotonus 29.85 27.93 10 8381 2488 110578420
Nightmare 29.30 27.93 24 8367 38839 110542069
Parkinsonism 28.75 27.93 19 8372 22168 110558740
Deep brain stimulation 28.16 27.93 5 8386 82 110580826

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04BX02 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Other dopaminergic agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D065098 Catechol O-Methyltransferase Inhibitors
CHEBI has role CHEBI:35470 central nervous system drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:48406 EC 2.1.1.6 (catechol <em>O</em>-methyltransferase) inhibitor
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:66956 antidyskinesia agent
CHEBI has role CHEBI:74518 anti-obesity agent
FDA MoA N0000175756 Catechol O-Methyltransferase Inhibitors
FDA EPC N0000175757 Catechol-O-Methyltransferase Inhibitor

Related Drugs by ATC class:

N04BX Other dopaminergic agents 3 drugs
budipineopicaponetolcapone

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Parkinson's disease indication 49049000 DOID:14330
Suicidal thoughts contraindication 6471006
Hallucinations contraindication 7011001
Dyskinesia contraindication 9748009
Peptic ulcer contraindication 13200003 DOID:750
Disorder of lung contraindication 19829001 DOID:850
Myocardial infarction contraindication 22298006 DOID:5844
Orthostatic hypotension contraindication 28651003
Obstruction of bile duct contraindication 30144000
Depressive disorder contraindication 35489007
Conduction disorder of the heart contraindication 44808001
Duodenal ulcer disease contraindication 51868009 DOID:1724
Diarrhea contraindication 62315008
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Open-angle glaucoma contraindication 84494001 DOID:1067
Kidney disease contraindication 90708001 DOID:557
Acute disease of cardiovascular system contraindication 128487001
Seizure disorder contraindication 128613002
Drug-induced psychosis contraindication 191483003 DOID:1742
Disease of liver contraindication 235856003 DOID:409
Retention of urine contraindication 267064002
Psychoneurotic personality disorder contraindication 268634009
Malignant melanoma contraindication 372244006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Gastric ulcer contraindication 397825006 DOID:10808




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.41 acidic
pKa2 13.34 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Catechol O-methyltransferase Enzyme INHIBITOR Ki 9.52 SCIENTIFIC LITERATURE CHEMBL
G-protein coupled receptor 35 GPCR EC50 5.25 CHEMBL
Alpha-ketoglutarate-dependent dioxygenase FTO Enzyme IC50 5.52 CHEMBL
Mitochondrial pyruvate carrier 2 Transporter INHIBITOR IC50 6.22 IUPHAR
Mitochondrial pyruvate carrier 1-like protein Transporter INHIBITOR IC50 6.20 IUPHAR
Catechol O-methyltransferase Enzyme IC50 7.89 CHEMBL

External reference:

IDSource
4021181 VUID
N0000148629 NUI
D00781 KEGG_DRUG
4021181 VANDF
C0165921 UMLSCUI
CHEBI:4798 CHEBI
PD9 PDB_CHEM_ID
CHEMBL953 ChEMBL_ID
DB00494 DRUGBANK_ID
C071192 MESH_SUPPLEMENTAL_RECORD_UI
5281081 PUBCHEM_CID
6647 IUPHAR_LIGAND_ID
6812 INN_ID
4975G9NM6T UNII
227109 RXNORM
66346 MMSL
8477 MMSL
d04460 MMSL
007684 NDDF
116116003 SNOMEDCT_US
387018000 SNOMEDCT_US
4975G9NM6T INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Entacapone HUMAN PRESCRIPTION DRUG LABEL 1 0527-1830 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
Entacapone HUMAN PRESCRIPTION DRUG LABEL 1 0615-8298 TABLET 200 mg ORAL ANDA 19 sections
Entacapone HUMAN PRESCRIPTION DRUG LABEL 1 0781-5578 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 13 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5613 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5625 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5637 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5641 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5654 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5669 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Entacapone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6822 TABLET, FILM COATED 200 mg ORAL ANDA 20 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-689 TABLET, FILM COATED 200 mg ORAL ANDA 27 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-690 TABLET, FILM COATED 200 mg ORAL ANDA 27 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-691 TABLET, FILM COATED 200 mg ORAL ANDA 27 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-692 TABLET, FILM COATED 200 mg ORAL ANDA 27 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-693 TABLET, FILM COATED 200 mg ORAL ANDA 27 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-694 TABLET, FILM COATED 200 mg ORAL ANDA 27 sections
Entacapone Human Prescription Drug Label 1 27241-049 TABLET 200 mg ORAL ANDA 13 sections
Entacapone Human Prescription Drug Label 1 27241-049 TABLET 200 mg ORAL ANDA 13 sections
Entacapone Human Prescription Drug Label 1 33342-260 TABLET 200 mg ORAL ANDA 19 sections
Carbidopa, Levodopa and Entacapone Human Prescription Drug Label 3 33342-491 TABLET, FILM COATED 200 mg ORAL ANDA 25 sections
Carbidopa, Levodopa and Entacapone Human Prescription Drug Label 3 33342-492 TABLET, FILM COATED 200 mg ORAL ANDA 25 sections
Carbidopa, Levodopa and Entacapone Human Prescription Drug Label 3 33342-493 TABLET, FILM COATED 200 mg ORAL ANDA 25 sections
Carbidopa, Levodopa and Entacapone Human Prescription Drug Label 3 33342-494 TABLET, FILM COATED 200 mg ORAL ANDA 25 sections
Carbidopa, Levodopa and Entacapone Human Prescription Drug Label 3 33342-495 TABLET, FILM COATED 200 mg ORAL ANDA 25 sections
Carbidopa, Levodopa and Entacapone Human Prescription Drug Label 3 33342-496 TABLET, FILM COATED 200 mg ORAL ANDA 25 sections
Entacapone HUMAN PRESCRIPTION DRUG LABEL 1 43353-996 TABLET, FILM COATED 200 mg ORAL NDA 21 sections
ENTACAPONE Human Prescription Drug Label 1 46708-478 TABLET, FILM COATED 200 mg ORAL ANDA 19 sections
carbidopa, levodopa and entacapone Human Prescription Drug Label 3 46708-795 TABLET, FILM COATED 200 mg ORAL ANDA 25 sections
carbidopa, levodopa and entacapone Human Prescription Drug Label 3 46708-796 TABLET, FILM COATED 200 mg ORAL ANDA 25 sections
carbidopa, levodopa and entacapone Human Prescription Drug Label 3 46708-797 TABLET, FILM COATED 200 mg ORAL ANDA 25 sections